Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Santora

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Bone|February 3, 2009
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trialNeil Binkley, Johann D Ringe, John I Reed, et al.
The Journal of Clinical Endocrinology and Metabolism|October 9, 2004
Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort StudyMichael R McClung, Richard D Wasnich, David J Hosking, et al.
AJR. American Journal of Roentgenology|April 1, 1984
Detection of mediastinal parathyroid glands by nonselective digital arteriographyA G Krudy, J L Doppman, D L Miller, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 31, 2011
Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic womenSue A Shapses, David L Kendler, Richard Robson, et al.
Obstetrics and Gynecology|April 12, 2003
Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosisMarjorie M Luckey, Nigel Gilchrist, Henry G Bone, et al.
Current Medical Research and Opinion|September 14, 2006
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trialRobert Recker, Paul Lips, Dieter Felsenberg, et al.
JAMA|December 12, 2001
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk AssessmentE S Siris, P D Miller, E Barrett-Connor, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 31, 2009
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone densityHenry G Bone, Michael R McClung, Christian Roux, et al.
Current Medical Research and Opinion|September 19, 2003
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled studyDavid Hosking, Silvano Adami, Dieter Felsenberg, et al.
JAMA|April 9, 1997
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study GroupsD B Karpf, D R Shapiro, E Seeman, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Bone|February 3, 2009
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trialNeil Binkley, Johann D Ringe, John I Reed, et al.
The Journal of Clinical Endocrinology and Metabolism|October 9, 2004
Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort StudyMichael R McClung, Richard D Wasnich, David J Hosking, et al.
AJR. American Journal of Roentgenology|April 1, 1984
Detection of mediastinal parathyroid glands by nonselective digital arteriographyA G Krudy, J L Doppman, D L Miller, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 31, 2011
Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic womenSue A Shapses, David L Kendler, Richard Robson, et al.
Obstetrics and Gynecology|April 12, 2003
Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosisMarjorie M Luckey, Nigel Gilchrist, Henry G Bone, et al.
Current Medical Research and Opinion|September 14, 2006
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trialRobert Recker, Paul Lips, Dieter Felsenberg, et al.
JAMA|December 12, 2001
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk AssessmentE S Siris, P D Miller, E Barrett-Connor, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 31, 2009
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone densityHenry G Bone, Michael R McClung, Christian Roux, et al.
Current Medical Research and Opinion|September 19, 2003
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled studyDavid Hosking, Silvano Adami, Dieter Felsenberg, et al.
JAMA|April 9, 1997
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study GroupsD B Karpf, D R Shapiro, E Seeman, et al.
Pageof 7